The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | CTCs as a biomarker of tumor burden in multiple myeloma
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, highlights the potential of assessing circulating tumor cells (CTCs) at diagnosis in multiple myeloma to improve tumor burden assessment and refine currently used risk stratification systems. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
